The FDA has approved the drug belinostat to treat patients with relapsed or refractory peripheral T-cell lymphoma.
Earlier today the FDA granted accelerated approval to ceritinib (Zykadia) for the treatment of patients with metastatic ALK-positive non-small-cell lung cancer (NSCLC).
The FDA has approved siltuximab (Sylvant) for the treatment of multicentric Castleman disease, a disorder of the lymph nodes that is similar to lymphoma and often treated with chemotherapy and radiation.
The FDA has approved an HPV DNA test to be used as a primary screening method for cervical cancer in women 25 and older. The test can also give insight into future risk of cervical cancer.
The FDA has approved the angiogenesis inhibitor ramucirumab for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma.
The FDA has approved ibrutinib (Imbruvica) for the treatment of patients with mantle-cell lymphoma (MCL), an aggressive and rare blood cancer.
The FDA today approved obinutuzumab (Gazyva) for the treatment of chronic lymphocytic leukemia, to be used in combination with chlorambucil.
The US Food and Drug Administration approved the multi-kinase inhibitor regorafenib (Stivarga) yesterday, for the treatment of patients with unresectable metastatic gastrointestinal stromal tumors (GIST) that no longer respond to imatinib and sunitinib.
The FDA has approved ado-trastuzumab emtansine (Kadcyla), known as T-DM1 in development, for the treatment of women with metastatic HER2-positive breast cancer.
The FDA has approved pomalidomide (Pomalyst) to treat patients with relapsed or refractory multiple myeloma who have received at least two prior therapies.